- CEO
- Swee Lian Woo
- Full Time Employees
- 1,771
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Guangzhou China
- IPO Date
- Dec 10, 2010
- Business
- ChemPartner PharmaTech Co., Ltd. is a contract research and contract development and manufacturing organization (CRO/CDMO) that provides integrated drug discovery, preclinical development, and biomanufacturing services to biotechnology and pharmaceutical companies worldwide. Founded in 2000 and headquartered in Shanghai, China, the company operates across two principal business divisions: Drug Discovery & Preclinical Research Services, and Biopharmaceutical Development & Manufacturing Services. Its comprehensive portfolio includes Discovery Chemistry, encompassing synthetic and medicinal chemistry, computer-aided drug design, compound library synthesis, and active pharmaceutical ingredient synthesis; Biologics Discovery, comprising antibody generation, hybridoma technology, phage display, single B-cell cloning, antibody engineering, and recombinant protein production; In Vitro Biology and In Vivo Pharmacology, providing target validation, high-throughput screening, enzymatic and cell-based assays, disease-specific animal models in oncology, immunology, and metabolic disorders, as well as exploratory toxicology; Drug Metabolism and Pharmacokinetics (DMPK), offering in vitro ADME profiling, in vivo pharmacokinetic/pharmacodynamic modeling, and bioanalytical testing; and CDMO Solutions, delivering cell line development, microbial fermentation, mammalian cell culture bioprocessing, analytical formulation development, and cGMP-compliant clinical and commercial manufacturing for biologics and small molecules. ChemPartner PharmaTech serves multinational pharmaceutical corporations, emerging biotech innovators, and life science research institutes across North America, Europe, China, and the broader Asia-Pacific region, operating major laboratory and production complexes in Shanghai, Chengdu, and Qidong, alongside commercial and technical support operations in South San Francisco, California. In recent strategic developments, the company finalized the divestiture of its legacy microecological nutrition business to establish itself as a dedicated, pure-play biopharmaceutical CRO/CDMO; accelerated the expansion of advanced therapeutic platforms, including antibody-drug conjugates (ADCs), targeted protein degradation (PROTACs), and complex peptide synthesis; upgraded its cGMP biologics manufacturing facilities to comply with FDA, EMA, and NMPA standards; and restructured its international business development framework to broaden strategic collaborations with global drug developers.